

Thomas Roth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1585439/publications.pdf>

Version: 2024-02-01

169
papers

9,563
citations

53794

45
h-index

40979

93
g-index

170
all docs

170
docs citations

170
times ranked

7445
citing authors

#	ARTICLE	IF	CITATIONS
1	Examining Patient Feedback and the Role of Cognitive Arousal in Treatment Non-response to Digital Cognitive-behavioral Therapy for Insomnia during Pregnancy. Behavioral Sleep Medicine, 2022, 20, 143-163.	2.1	18
2	Efficacy of the triple-combination SM-1 in a 5-h phase advance transient insomnia model. Sleep and Biological Rhythms, 2022, 20, 47-52.	1.0	0
3	Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurology, The, 2022, 21, 125-139.	10.2	91
4	Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder. Sleep Medicine, 2022, 90, 249-257.	1.6	6
5	DSM-5 insomnia disorder in pregnancy: associations with depression, suicidal ideation, and cognitive and somatic arousal, and identifying clinical cutoffs for detection. SLEEP Advances, 2022, 3, zpac006.	0.2	13
6	Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial. CNS Drugs, 2022, 36, 377-387.	5.9	8
7	Validation of Somno-Art Software, a novel approach of sleep staging, compared with polysomnography in disturbed sleep profiles. SLEEP Advances, 2022, 3, .	0.2	2
8	Performance of Somno-Art Software compared to polysomnography interscorer variability: A multi-center study. Sleep Medicine, 2022, 96, 14-19.	1.6	5
9	Typologies of individuals vulnerable to insomnia: a two-step cluster analysis. Sleep and Biological Rhythms, 2021, 19, 33-44.	1.0	6
10	Sleep and alertness disturbance and substance use disorders: A bi-directional relation. Pharmacology Biochemistry and Behavior, 2021, 203, 173153.	2.9	30
11	490 Efficacy of FT218 on Polysomnographic Measures of Sleep Continuity in Patients With Narcolepsy: Results From the REST-ON Trial. Sleep, 2021, 44, A193-A194.	1.1	0
12	336 Effect of Lemborexant Versus Placebo and Zolpidem on REM Sleep by Quarter Night Intervals in Older Adults with Insomnia Disorder. Sleep, 2021, 44, A134-A134.	1.1	0
13	489 Pivotal Phase 3 Study of FT218, a Once-Nightly Sodium Oxybate Formulation, in Patients With Narcolepsy: REST-ON Primary Results. Sleep, 2021, 44, A193-A193.	1.1	2
14	488 REST-ON: Efficacy of FT218 for Daytime Sleepiness, Sleep Quality, Hallucinations, and Sleep Paralysis in Patients With Narcolepsy. Sleep, 2021, 44, A192-A193.	1.1	0
15	How well can a large number of polysomnography sleep measures predict subjective sleep quality in insomnia patients?. Sleep Medicine, 2020, 67, 137-146.	1.6	10
16	Depression and suicidal ideation in pregnancy: exploring relationships with insomnia, short sleep, and nocturnal rumination. Sleep Medicine, 2020, 65, 62-73.	1.6	58
17	Nocturnal cognitive arousal is associated with objective sleep disturbance and indicators of physiologic hyperarousal in good sleepers and individuals with insomnia disorder. Sleep Medicine, 2020, 71, 151-160.	1.6	42
18	Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension. Journal of Clinical Sleep Medicine, 2020, 16, 1455-1467.	2.6	8

#	ARTICLE	IF	CITATIONS
19	A randomized controlled trial of digital cognitive behavioral therapy for insomnia in pregnant women. <i>Sleep Medicine</i> , 2020, 72, 82-92.	1.6	86
20	Mindfulness and nocturnal rumination are independently associated with symptoms of insomnia and depression during pregnancy. <i>Sleep Health</i> , 2020, 6, 185-191.	2.5	23
21	<p>Sexual function and distress in postmenopausal women with chronic insomnia: exploring the role of stress dysregulation</p>. <i>Nature and Science of Sleep</i> , 2019, Volume 11, 141-153.	2.7	11
22	0372 Arousability of Insomnia Patients is Not Impacted by the Orexin Antagonist Suvorexant (10 mg and) Tj ETQq000 rgBT /Overlock 1	1.1	0
23	0338 Insomnia in Late Pregnancy: Characterizing Phenotypes and Identifying Associated Factors. <i>Sleep</i> , 2019, 42, A138-A138.	1.1	1
24	0610 Pharmacokinetics And Dose Proportionality Of FT218, An Investigational Controlled Release Formulation Of Sodium Oxybate For Once Nightly Dosing. <i>Sleep</i> , 2019, 42, A243-A243.	1.1	1
25	Treating insomnia improves depression, maladaptive thinking, and hyperarousal in postmenopausal women: comparing cognitive-behavioral therapy for insomnia (CBTI), sleep restriction therapy, and sleep hygiene education. <i>Sleep Medicine</i> , 2019, 55, 124-134.	1.6	83
26	Hyperarousal in insomnia: pre-sleep and diurnal cortisol levels in response to chronic zolpidem treatment. <i>Sleep Medicine</i> , 2019, 61, 52-56.	1.6	9
27	0609 Pharmacokinetics And Formulation Selection Of Ft218, An Investigational Controlled-release Sodium Oxybate Formulation Designed For Once Nightly Dosing. <i>Sleep</i> , 2019, 42, A242-A243.	1.1	1
28	Irritable Bowel Syndrome, Immune Fitness, and Insomnia: Results from an Online Survey Among People Reporting Sleep Complaints. <i>Sleep and Vigilance</i> , 2019, 3, 121-129.	0.8	13
29	Relation between ambulatory actigraphy and laboratory polysomnography in insomnia practice and research. <i>Journal of Sleep Research</i> , 2019, 28, e12854.	3.2	37
30	Development of the Nocturia Sleep Quality Scale: a patient-reported outcome measure of sleep impact related to nocturia. <i>Sleep Medicine</i> , 2019, 59, 101-106.	1.6	3
31	Shift Work: A Perspective on Shift Work Disorderâ€™s Prevention the Answer?. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1863-1865.	2.6	7
32	0337 Insomniacs in Late Pregnancy are Clinically Depressed: Exploring the Role of Nocturnal Rumination. <i>Sleep</i> , 2019, 42, A138-A138.	1.1	0
33	Pharmacodynamic and pharmacokinetic profile of SMâ€1, a tripleâ€drug combination to increase total sleep time. <i>Human Psychopharmacology</i> , 2019, 34, e2716.	1.5	1
34	Efficacy of SMâ€1 in a transient insomnia model. <i>Human Psychopharmacology</i> , 2019, 34, e2713.	1.5	2
35	<p></p>Insomnia, Short Sleep, And Snoring In Mid-To-Late Pregnancy: Disparities Related To Poverty, Race, And Obesity</p>. <i>Nature and Science of Sleep</i> , 2019, Volume 11, 301-315.	2.7	34
36	Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. <i>Journal of Sleep Research</i> , 2019, 28, e12782.	3.2	39

#	ARTICLE	IF	CITATIONS
37	A novel forehead temperature-regulating device for insomnia: a randomized clinical trial. <i>Sleep</i> , 2018, 41, .	1.1	16
38	Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts. <i>Sleep</i> , 2018, 41, .	1.1	23
39	Assessing Stress-Induced Sleep Reactivity in College Students: The European Portuguese Version of the Ford Insomnia Response to Stress Test (FIRST). <i>Behavioral Sleep Medicine</i> , 2018, 16, 337-346.	2.1	8
40	The Association of Insomnia, Perceived Immune Functioning, and Irritable Bowel Syndrome Complaints. <i>Journal of Clinical Medicine</i> , 2018, 7, 238.	2.4	18
41	International Task Force on Benzodiazepines. <i>Psychotherapy and Psychosomatics</i> , 2018, 87, 193-194.	8.8	26
42	Hyperarousal and sleep reactivity in insomnia: current insights. <i>Nature and Science of Sleep</i> , 2018, Volume 10, 193-201.	2.7	194
43	The Prescription of Benzodiazepines for Panic Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 283-285.	1.4	17
44	Inclusion and Exclusion Criteria of Clinical Trials for Insomnia. <i>Journal of Clinical Medicine</i> , 2018, 7, 206.	2.4	15
45	Increasing presurgery sleep reduces postsurgery pain and analgesic use following joint replacement: a feasibility study. <i>Sleep Medicine</i> , 2017, 33, 109-113.	1.6	26
46	Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 791-802.	1.2	51
47	Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data. <i>Psychopharmacology</i> , 2017, 234, 1703-1711.	3.1	13
48	Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. <i>Sleep Medicine</i> , 2017, 40, 53-57.	1.6	24
49	Alcohol Hangover, Sleep Quality, and Daytime Sleepiness. <i>Sleep and Vigilance</i> , 2017, 1, 37-41.	0.8	21
50	Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. <i>Journal of Sleep Research</i> , 2017, 26, 407-414.	3.2	43
51	Effectiveness of Benzodiazepine Receptor Agonists in the Treatment of Insomnia: An Examination of Response and Remission Rates. <i>Sleep</i> , 2017, 40, .	1.1	38
52	Post Hoc Analysis of Data from Two Clinical Trials Evaluating the Minimal Clinically Important Change in International Restless Legs Syndrome Sum Score in Patients with Restless Legs Syndrome (Willis-Ekbom Disease). <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 63-70.	2.6	5
53	Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. <i>Journal of Clinical Sleep Medicine</i> , 2016, 12, 1215-1225.	2.6	51
54	Sleep, Sleep Disorders, and Mild Traumatic Brain Injury. What We Know and What We Need to Know: Findings from a National Working Group. <i>Neurotherapeutics</i> , 2016, 13, 403-417.	4.4	107

#	ARTICLE	IF	CITATIONS
55	Prevalence and Predictors of Prescription Sleep Aid Use among Individuals with DSM-5 Insomnia: The Role of Hyperarousal. <i>Sleep</i> , 2016, 39, 825-832.	1.1	36
56	Assessing sleep architecture and continuity measures through the analysis of heart rate and wrist movement recordings in healthy subjects: comparison with results based on polysomnography. <i>Sleep Medicine</i> , 2016, 21, 47-56.	1.6	46
57	Towards quantitative cutoffs for insomnia: how current diagnostic criteria mischaracterize remission. <i>Sleep Medicine</i> , 2016, 26, 62-68.	1.6	13
58	A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw022.	2.1	33
59	Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. <i>Biological Psychiatry</i> , 2016, 79, 136-148.	1.3	201
60	Length polymorphism in the <i>PER3</i> gene is associated with sleepiness and maladaptive circadian phase in night shift workers. <i>Journal of Sleep Research</i> , 2015, 24, 254-261.	3.2	17
61	Differential Sleep, Sleepiness, and Neurophysiology in the Insomnia Phenotypes of Shift Work Disorder. <i>Sleep</i> , 2015, 38, 119-126.	1.1	46
62	The Nature of Stable Insomnia Phenotypes. <i>Sleep</i> , 2015, 38, 127-138.	1.1	78
63	Insomnia in Shift Work Disorder Relates to Occupational and Neurophysiological Impairment. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 457-465.	2.6	17
64	Sleep maintenance difficulties in insomnia are associated with increased incidence of hypertension. <i>Sleep Health</i> , 2015, 1, 50-54.	2.5	15
65	Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial. <i>Sleep Medicine</i> , 2015, 16, 838-844.	1.6	24
66	Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial. <i>Sleep Medicine</i> , 2015, 16, 831-837.	1.6	19
67	Effects of reduced time in bed on daytime sleepiness and recovery sleep in fibromyalgia and rheumatoid arthritis. <i>Journal of Psychosomatic Research</i> , 2015, 79, 27-31.	2.6	3
68	Sleep Disturbance in Substance Use Disorders. <i>Psychiatric Clinics of North America</i> , 2015, 38, 793-803.	1.3	57
69	Effects of Excessive Daytime Sleepiness and Fatigue on Overall Health and Cognitive Function. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1145-e1145.	2.2	17
70	The Effect of Comorbid Psychiatric and Medical Illnesses on Sleep Disorder Treatment. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1146-e1146.	2.2	3
71	Time to Response with Sodium Oxybate for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 427-432.	2.6	37
72	The interplay between daily affect and sleep: a 2-week study of young women. <i>Journal of Sleep Research</i> , 2014, 23, 636-645.	3.2	80

#	ARTICLE	IF	CITATIONS
73	Electroencephalographic Power Spectral Density Profile of the Orexin Receptor Antagonist Suvorexant in Patients with Primary Insomnia and Healthy Subjects. <i>Sleep</i> , 2014, 37, 1609-1619.	1.1	44
74	The Effect of Insomnia on Tinnitus. <i>Annals of Otology, Rhinology and Laryngology</i> , 2014, 123, 696-700.	1.1	38
75	A Generalized Estimating Equation Approach to Analysis of Maintenance of Wakefulness Testing in a Study of Lisdexamfetamine Dimesylate, Armodafinil, and Placebo in Sleep-Deprived Adults. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 642-644.	1.4	0
76	Validation of the Japanese version of the Ford Insomnia Response to Stress Test and the association of sleep reactivity with trait anxiety and insomnia. <i>Sleep Medicine</i> , 2014, 15, 196-202.	1.6	39
77	A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. <i>Sleep Medicine Reviews</i> , 2014, 18, 261-271.	8.5	45
78	Gender influences on efficacy and safety of sublingual zolpidem tartrate for middle-of-the-night awakening in insomnia. <i>Human Psychopharmacology</i> , 2014, 29, 25-30.	1.5	5
79	Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2014, 13, 461-471.	10.2	437
80	A seven day actigraphy-based study of rumination and sleep disturbance among young adults with depressive symptoms. <i>Journal of Psychosomatic Research</i> , 2014, 77, 70-75.	2.6	100
81	Residual Effects of Low-Dose Sublingual Zolpidem on Highway Driving Performance the Morning after Middle-of-the-Night Use. <i>Sleep</i> , 2014, 37, 489-496.	1.1	40
82	Moderators and Mediators of the Relationship Between Stress and Insomnia: Stressor Chronicity, Cognitive Intrusion, and Coping. <i>Sleep</i> , 2014, 37, 1199-1208A.	1.1	99
83	Stress and Sleep Reactivity: A Prospective Investigation of the Stress-Diathesis Model of Insomnia. <i>Sleep</i> , 2014, 37, 1295-1304.	1.1	244
84	Novel Sublingual Low-Dose Zolpidem Tablet Reduces Latency to Sleep Onset following Spontaneous Middle-of-the-Night Awakening in Insomnia in a Randomized, Double-Blind, Placebo-Controlled, Outpatient Study. <i>Sleep</i> , 2013, 36, 189-196.	1.1	40
85	Toward a classification of medications for sleep and circadian rhythm disorders. <i>Nature and Science of Sleep</i> , 2013, 5, 143.	2.7	4
86	Disrupted Nighttime Sleep in Narcolepsy. <i>Journal of Clinical Sleep Medicine</i> , 2013, 09, 955-965.	2.6	156
87	Appropriate therapeutic selection for patients with shift work disorder. <i>Sleep Medicine</i> , 2012, 13, 335-341.	1.6	35
88	Shift Work Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e09.	2.2	11
89	The Challenges of Interpreting Residual Effects of Hypnotics. <i>Sleep</i> , 2011, 34, 1285-1286.	1.1	1
90	Effect of Gaboxadol on Patient-reported Measures of Sleep and Waking Function in Patients with Primary Insomnia: Results from Two Randomized, Controlled, 3-month Studies. <i>Journal of Clinical Sleep Medicine</i> , 2010, 06, 30-39.	2.6	25

#	ARTICLE	IF	CITATIONS
91	Nonrestorative Sleep as a Distinct Component of Insomnia. <i>Sleep</i> , 2010, 33, 449-458.	1.1	89
92	The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials. <i>Current Medical Research and Opinion</i> , 2010, 26, 2411-2419.	1.9	55
93	An Introduction to the Clinical Correlates of Disrupted Slow-Wave Sleep. <i>Journal of Clinical Psychiatry</i> , 2010, 71, e09.	2.2	4
94	Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies. <i>Journal of Clinical Sleep Medicine</i> , 2010, 6, 30-9.	2.6	12
95	Slow Wave Sleep: Does it Matter?. <i>Journal of Clinical Sleep Medicine</i> , 2009, 5, .	2.6	20
96	Hypnotic use for insomnia management in chronic obstructive pulmonary disease. <i>Sleep Medicine</i> , 2009, 10, 19-25.	1.6	71
97	Slow wave sleep: does it matter?. <i>Journal of Clinical Sleep Medicine</i> , 2009, 5, S4-5.	2.6	9
98	Comorbid insomnia: current directions and future challenges. <i>American Journal of Managed Care</i> , 2009, 15 Suppl, S6-13.	1.1	30
99	Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea. <i>Sleep and Breathing</i> , 2008, 12, 53-62.	1.7	41
100	Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate. <i>Human Psychopharmacology</i> , 2008, 23, 13-20.	1.5	21
101	Periodic Limb Movements During Sleep: Population Prevalence, Clinical Correlates, and Racial Differences. <i>Sleep</i> , 2008, , .	1.1	42
102	Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings. <i>Sleep</i> , 2008, 31, 1277-84.	1.1	44
103	Insomnia: Pathophysiology and implications for treatment. <i>Sleep Medicine Reviews</i> , 2007, 11, 71-79.	8.5	171
104	Insomnia: Definition, Prevalence, Etiology, and Consequences. <i>Journal of Clinical Sleep Medicine</i> , 2007, 3, .	2.6	689
105	The Nature of Insomnia. <i>CNS Spectrums</i> , 2007, 12, 3-5.	1.2	15
106	Efficacy and Tolerability of Indiplon in Transient Insomnia. <i>Journal of Clinical Sleep Medicine</i> , 2007, 03, 374-379.	2.6	22
107	Sleep Therapy: New Generation Pharmacologic Agents for Managing Insomnia. <i>Journal of Clinical Sleep Medicine</i> , 2007, 3, .	2.6	1
108	Insomnia: definition, prevalence, etiology, and consequences. <i>Journal of Clinical Sleep Medicine</i> , 2007, 3, S7-10.	2.6	462

#	ARTICLE	IF	CITATIONS
109	Understanding neuronal pathways: novel targets for the management of insomnia. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 5, 4-5.	2.2	1
110	A physiologic basis for the evolution of pharmacotherapy for insomnia. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 5, 13-8.	2.2	6
111	Introduction: narcolepsy and excessive daytime sleepiness: from the bench to the bedside. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 13, 4.	2.2	0
112	Narcolepsy: treatment issues. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 13, 16-9.	2.2	1
113	Sleep Problems, Comorbid Mental Disorders, and Role Functioning in the National Comorbidity Survey Replication. <i>Biological Psychiatry</i> , 2006, 60, 1364-1371.	1.3	349
114	Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. <i>Sleep Medicine</i> , 2006, 7, 312-318.	1.6	265
115	Tiagabine Increases Slow-Wave Sleep in a Dose-Dependent Fashion Without Affecting Traditional Efficacy Measures in Adults With Primary Insomnia. <i>Journal of Clinical Sleep Medicine</i> , 2006, 02, 35-41.	2.6	50
116	Effect of Tiagabine on Sleep in Elderly Subjects With Primary Insomnia: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Sleep</i> , 2006, 29, 335-341.	1.1	71
117	Ramelteon (TAK-375), A Selective MT1/MT2-Receptor Agonist, Reduces Latency to Persistent Sleep in a Model of Transient Insomnia Related to a Novel Sleep Environment. <i>Sleep</i> , 2005, , .	1.1	37
118	Alcohol, Alcoholism, and Sleep. , 2005, , 867-871.		3
119	Shift Work Sleep Disorder: Prevalence and Consequences Beyond that of Symptomatic Day Workers. <i>Journal of Clinical Sleep Medicine</i> , 2005, 01, 102-107.	2.6	0
120	Drugs of Abuse and Sleep. , 2005, , 873-877.		0
121	An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. <i>Sleep Medicine</i> , 2005, 6, 487-495.	1.6	218
122	The Assessment of Treatment Efficacy. <i>Journal of Clinical Sleep Medicine</i> , 2005, 01, .	2.6	0
123	Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. <i>Sleep</i> , 2005, 28, 303-7.	1.1	125
124	Prevalence, associated risks, and treatment patterns of insomnia. <i>Journal of Clinical Psychiatry</i> , 2005, 66 Suppl 9, 10-3; quiz 42-3.	2.2	27
125	Evolution of insomnia: current status and future direction. <i>Sleep Medicine</i> , 2004, 5, S23-S30.	1.6	100
126	Vulnerability to Stress-related Sleep Disturbance and Hyperarousal. <i>Sleep</i> , 2004, 27, 285-291.	1.1	364

#	ARTICLE	IF	CITATIONS
127	Measuring treatment efficacy in insomnia. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 8, 8-12.	2.2	3
128	Characteristics and determinants of normal sleep. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 16, 8-11.	2.2	5
129	Insomnia: Epidemiology, characteristics, and consequences. <i>Clinical Cornerstone</i> , 2003, 5, 5-15.	0.7	294
130	Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. <i>Sleep Medicine</i> , 2003, 4, 275-280.	1.6	89
131	The Pediatric Daytime Sleepiness Scale (PDSS): Sleep Habits and School Outcomes in Middle-school Children. <i>Sleep</i> , 2003, , .	1.1	157
132	Treatment regimen and hypnotic self-administration. <i>Psychopharmacology</i> , 2001, 155, 11-17.	3.1	18
133	Effects of rapid versus slow accumulation of eight hours of sleep loss. <i>Psychophysiology</i> , 2001, 38, 979-987.	2.4	175
134	Scoring Reliability of the Multiple Sleep Latency Test in a Clinical Population. <i>Sleep</i> , 2000, 23, 1-3.	1.1	36
135	Eight Weeks of Non-Nightly Use of Zolpidem for Primary Insomnia. <i>Sleep</i> , 2000, 23, 1-10.	1.1	136
136	Ethanol as a Hypnotic in Insomniacs Self Administration and Effects on Sleep and Mood. <i>Neuropsychopharmacology</i> , 1999, 20, 279-286.	5.4	147
137	Electrophysiological Assessment (The Multiple Sleep Latency Test) of the Biphasic Effects of Ethanol in Humans. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 231-235.	2.4	72
138	Efficacy and Tolerability of 14-Day Administration of Zaleplon 5mg and 10mg for the Treatment of Primary Insomnia. <i>Clinical Drug Investigation</i> , 1998, 16, 347-354.	2.2	64
139	Response to Rye and Bliwise. <i>Sleep</i> , 1997, 20, 814-814.	1.1	0
140	Hypnotic self administration: forced-choice versus single-choice. <i>Psychopharmacology</i> , 1997, 133, 121-126.	3.1	18
141	Hypnotic self administration and dose escalation. <i>Psychopharmacology</i> , 1996, 127, 150-154.	3.1	55
142	Social and Economic Consequences of Sleep Disorders. <i>Sleep</i> , 1996, 19, S46-S47.	1.1	8
143	Management of Insomniac Patients. <i>Sleep</i> , 1996, 19, S52-S53.	1.1	22
144	Clinical Development of Hypnotics. <i>Sleep</i> , 1996, 19, S48-S49.	1.1	0

#	ARTICLE	IF	CITATIONS
145	The Frequency of Multiple Sleep Onset REM Periods Among Subjects With No Excessive Daytime Sleepiness. <i>Sleep</i> , 1996, 19, 727-730.	1.1	186
146	Sleep restriction, ethanol effects and time of day. <i>Human Psychopharmacology</i> , 1996, 11, 199-204.	1.5	7
147	Sleep restriction, ethanol effects and time of day. <i>Human Psychopharmacology</i> , 1996, 11, 199-204.	1.5	1
148	Zolpidem in the Treatment of Transient Insomnia: A Double-Blind, Randomized Comparison With Placebo. <i>Sleep</i> , 1995, 18, 246-251.	1.1	100
149	Alcohol-Induced Sleepiness and Memory Function. <i>Alcohol Health and Research World</i> , 1995, 19, 130-135.	0.2	5
150	Heart rate changes in chronic insomnia. <i>Stress and Health</i> , 1994, 10, 261-266.	0.5	72
151	Residual Sedating Effects of Ethanol. <i>Alcoholism: Clinical and Experimental Research</i> , 1994, 18, 831-834.	2.4	25
152	Sleepiness and Ethanol Effects on Simulated Driving. <i>Alcoholism: Clinical and Experimental Research</i> , 1994, 18, 154-158.	2.4	125
153	Benzodiazepine associated reversal of the effects of experimental sleep fragmentation. <i>Human Psychopharmacology</i> , 1993, 8, 351-356.	1.5	4
154	Replacement of Benzodiazepines with ???Old-Fashioned??? Hypnotics. <i>Drug Safety</i> , 1993, 9, 149-150.	3.2	5
155	Effects of Ethanol, Diphenhydramine, and Triazolam after a Nap. <i>Neuropsychopharmacology</i> , 1993, 9, 239-245.	5.4	25
156	Sedative Effects and Plasma Concentrations Following Single Doses of Triazolam, Diphenhydramine, Ethanol and Placebo. <i>Sleep</i> , 1993, 16, 301-305.	1.1	50
157	Sedating Effects of Ethanol And Time of Drinking. <i>Alcoholism: Clinical and Experimental Research</i> , 1992, 16, 553-557.	2.4	46
158	Individual Differences in the Sedating Effects of Ethanol. <i>Alcoholism: Clinical and Experimental Research</i> , 1990, 14, 400-404.	2.4	16
159	Fragmented Sleep, Daytime Somnolence and Age in Narcolepsy. <i>Clinical EEG (electroencephalography)</i> , 1989, 20, 49-54.	0.9	17
160	The dose effects of zopiclone. <i>Human Psychopharmacology</i> , 1989, 4, 41-46.	1.5	10
161	The Effects of Acute Sleep Restriction and Extension on Sleep Efficiency. <i>International Journal of Neuroscience</i> , 1988, 43, 139-143.	1.6	28
162	Daytime Alertness in Patients with Chronic Insomnia Compared with Asymptomatic Control Subjects. <i>Sleep</i> , 1988, 11, 54-60.	1.1	284

#	ARTICLE	IF	CITATIONS
163	Experimental sleep fragmentation in normal subjects. <i>International Journal of Neuroscience</i> , 1987, 33, 207-214.	1.6	113
164	Ethanol and Caffeine Effects on Daytime Sleepiness/Alertness. <i>Sleep</i> , 1987, , .	1.1	22
165	Sleep-Wake Abnormalities in Narcolepsy. <i>Sleep</i> , 1986, 9, 189-193.	1.1	34
166	The Alerting Effects of Naps in Sleep-Deprived Subjects. <i>Psychophysiology</i> , 1986, 23, 403-408.	2.4	81
167	Daytime Sleepiness and Antihistamines. <i>Sleep</i> , 1984, 7, 137-141.	1.1	86
168	Pharmacology and Hypnotic Efficacy of Triazolam. <i>Pharmacotherapy</i> , 1983, 3, 137-145.	2.6	43
169	Flurazepam for Short-Term Treatment of Complaints of Insomnia. <i>Journal of Clinical Pharmacology</i> , 1982, 22, 290-296.	2.0	13